

## Drug Bio transformation:

- \* Humans are exposed always to foreign compounds called Xenobiotics through GIT, Skin, lung, ...
  - \* Xenobiotics excreted by kidney are
    - Smaller Polar molecule
    - ionized at physiological pH
  - \* many drugs are lipophilic at physiological pH, and readily absorbed from glomerular filtrate in the nephron, but **lipophilic drug which bind to plasma protein** are not.
  - \* Such drugs are metabolized in liver to more polar molecules that can be excreted in Urine, Bile
  - \* Metabolic product are often less active than the parent drug and may be inactive. but there are an exception.
- Some Drug Metabolism have enhanced activity or even toxicity
- Some Drugs are inactive and need activation  
By metabolism as prodrug
- Some Drug are metabolised into toxins

Examples:

- ① paracetamol may convert to the hepatotoxic N-acetyl-p-benzogquinone
- ② Halothane is metabolised and release free radical that call hepatotoxic

\* Bio transformation Rxn can be classified as (the doctor said it is philosopher technique)

Phase 1

Phase 2

\* Converting the drug to more polar metabolites by introducing (Adding or Un masking) polar group

\* phase 2 is Conjugation reaction (Conjugation rxn with an endogenous substrate such as

-OH      -SH      -NH<sub>2</sub>

Glucuronic acid      Sulfuric acid      acetyl CoA      Glutathione

Which makes the drug more polar  
= more excretion by the kidney

\* Conjugated drug usually excreted by Urine and bile

\* the metabolites can be

less active      inactive      more active

Oxidation      Reduction      Hydrolysis

\* Many phase 1 product need phase 2

Oxidation      Reduction      Hydrolysis

\* Conjugation is synthetic rxns, involve high-energy intermediates and specific transfer enzymes called **transferases**

\* phase 2 rxns are relatively faster than phase 1.

- \* phase 1
- \* most oxidation-reduction rxns in drug metabolism carried by microsomal mixed function oxidase or Cytochrome P450 enzyme (I really don't know what's that mean)
- \* Cytochrome P450 is located in Endoplasmic reticulum.
- \* they have low specificity and slow rxn rate.
- \* High lipid solubility is common to the wide variety of structurally unrelated drugs metabolized by this system

Reaction Class	Structural Change	①	Drug Substrates	②		
Oxidations						
Cytochrome P450-dependent oxidations:						
Aromatic hydroxylations		①	Acetanilide, propranolol, phenobarbital, phenytoin, phenylbutazone, amphetamine, warfarin, 17α-ethinyl estradiol, naphthalene, benzpyrene	N-Oxidation		Aniline, chlorphentermine 2-Acetylaminofluorene, acetaminophen
Aliphatic hydroxylations	$\text{RCH}_2\text{CH}_3 \rightarrow \text{RCH}_2\text{CH}_2\text{OH}$ $\text{RCH}_2\text{CH}_3 \rightarrow \text{RCH}(\text{OH})_2$	①	Amobarbital, pentobarbital, secobarbital, chlorpromazine, ibuprofen, meprobamate, glutethimide, phenylbutazone, digitoxin	S-Oxidation		Thioridazine, cimetidine, chlorpromazine
Epoxidation	$\text{RCH}=\text{CHR} \rightarrow \begin{array}{c} \text{H} \\   \\ \text{O} \\   \\ \text{H} \\ \diagdown \\ \text{C}-\text{C}-\text{R} \end{array}$	①	Aldrin	Deamination		Amphetamine, diazepam
Oxidative dealkylation				Desulfuration		Thiopental
N-Dealkylation	$\text{RNHCH}_3 \rightarrow \text{RNH}_2 + \text{CH}_2\text{O}$	②	Morphine, ethylmorphine, benzphetamine, aminopyrine, caffeine, theophylline			Parathion Carbon tetrachloride
O-Dealkylation	$\text{ROCH}_3 \rightarrow \text{ROH} + \text{CH}_2\text{O}$	②	Codeine, p-nitroanisole			
S-Dealkylation	$\text{RSCH}_3 \rightarrow \text{RSH} + \text{CH}_2\text{O}$	②	6-Methylthiopurine, methitural			
Cytochrome P450-independent oxidations:		③				
Flavin monooxygenase (Ziegler's enzyme)	$\text{R}_3\text{N} \rightarrow \text{R}_3\text{N}^+ \rightarrow \text{O}^- \xrightarrow{\text{H}^+} \text{R}_3\text{N}^{\bullet}\text{OH}$	③	Chlorpromazine, amitriptyline, benzphetamine			
	$\text{RCH}_2\text{N}-\text{CH}_2\text{R} \rightarrow \text{RCH}_2-\overset{\text{OH}}{\underset{\text{H}}{\text{N}}} \text{CH}_2\text{R} \rightarrow \text{RCH}=\text{N}-\text{CH}_2\text{R}$	③	Desipramine, nortriptyline			
		③	Methimazole, propylthiouracil			
Amine oxidases	$\text{RCH}_2\text{NH}_2 \rightarrow \text{RCHO} + \text{NH}_3$	③	Phenylethylamine, epinephrine			
Dehydrogenations	$\text{RCH}_2\text{OH} \rightarrow \text{RCHO}$	③	Ethanol			
Reductions						
Azo reductions	$\text{RN}=\text{NR}_1 \rightarrow \text{RNH}-\text{NHR}_1 \rightarrow \text{RNH}_2 + \text{R}_1\text{NH}_2$		Prontosil, tartrazine			
Nitro reductions	$\text{RNO}_2 \rightarrow \text{RNO} \rightarrow \text{RNHOH} \rightarrow \text{RNH}_2$		Nitrobenzene, chloramphenicol, clonazepam, dantrolene			
Carbonyl reductions	$\text{RCR}' \xrightarrow[\text{OH}]{\text{O}} \text{RCHR}'$		Metyrapone, methadone, naloxone			
Hydrolyses						
Esters	$\text{R}_1\text{COOR}_2 \rightarrow \text{R}_1\text{COOH} + \text{R}_2\text{OH}$		Procaine, succinylcholine, aspirin, clofibrate, methylphenidate			
Amides	$\text{RCONHR}_1 \rightarrow \text{RICOOH} + \text{R}_1\text{NH}_2$		Procainamide, lidocaine, indomethacin			

- \* Human liver Cytochrome P450 Enzyme.
- \* there are numerous P450 isoenzymes as **CYP1A2**, **CYP2C9**, **CYP2D6**, **CYP2E1**, **CYP3A4**, **CYP2A6**, **CYP2B6**, **CYP2C19**, **CYP2C8**
- \* CYP3A4 is account for 30% of Human liver P450 content and metabolise more 50% of Therapeutic drugs
- \* CYP2C9 is account for 20% of Human liver P450 content and CYP2D6 account for 25%
- \* CYP1A2 is account for 15% of liver P450, but it activate carcinogens.

\* Phase 2 → the drug is conjugated with endogenous substrate yield drug conjugates

\* Conjugates are polar molecule readily excreted and inactivated.

#### ④ Glutathione (GSH) transferase

\* the donor is Glutathione which is Gly - Cys - Glu

\* GSH is nucleophile that reacts with electrophiles.

and it replace Halogens and Conjugate epoxides.

\* Glutathione Conjugates don't appear in Urine but in bile

\* they are metabolised further to Cys - Conjugates then

to mercaptouric acid ( $\pi$ -acetylated Cys conjugates) that

appear in Urine by active transport process.

#### ⑤ S-Adenosyl-L-methionine (SAM)

\* mediate O-, N-, S- methylation

of drug and Xenobiotics.

By methyl transferases (MTS).

Diagram: A central cloud-like shape labeled "Bio transformation Rxns in phase II" is connected to three numbered boxes below it. Box 1 (red) contains "Uridine 5'-diphosphate (UDP)-glucuronosyl transferase (UGTs)" and "most dominant Conjugation enzyme." It also lists "-OH", "-NH", "-SH", "-COOH", and "-NH<sub>2</sub>OH" as substrates. Box 2 (blue) contains "Sulfo transferases (SULTs)" and "phosphoadenosine 5'-phosphosulfate (PAPS)". It notes that inorganic sulfate is a limiting factor and a source from food or S-containing amino acids. Box 3 (red) contains "N-acetyl transferase (NAT)" and "Utilize Acetyl-CoA as the endogenous cofactor for Conjugation". A red arrow points from the top left towards the UGTs box, and a blue arrow points from the top right towards the NAT box.

① Uridine 5'-diphosphate (UDP)-glucuronosyl transferase (UGTs)

most dominant Conjugation enzyme.

Can work on  
-OH  
-NH  
-SH  
-COOH  
-NH<sub>2</sub>OH

#### Bio transformation Rxns in phase II

##### ② Sulfo transferases (SULTs)

\* phosphoadenosine 5'-phosphosulfate (PAPS)

\* inorganic sulfate is limiting factor and it is source from food or S-containing amino acids.

\* almost all chemicals that glucuronidated are sulfated

\* infant more capable of sulfation than adults.

##### ③ N-acetyl transferase (NAT)

\* Utilize Acetyl-CoA as the endogenous cofactor for Conjugation

Type of Conjugation	Endogenous Reactant	Transferase (Location)	Types of Substrates	Examples
Glucuronidation	UDP glucuronic acid	UDP glucuronosyltransferase (microsomes)	Phenols, alcohols, carboxylic acids, hydroxylamines, sulfonamides	Nitrophenol, morphine, acetaminophen, diazepam, N-hydroxydapsone, sulfathiazole, meprobamate, digitoxin, digoxin
Acetylation	Acetyl-CoA	N-Acetyltransferase (cytosol)	Amines	Sulfonamides, isoniazid, clonazepam, dapsone, mescaline
Glutathione conjugation	Glutathione (GSH)	GSH-S-transferase (cytosol, microsomes)	Epoxides, arene oxides, nitro groups, hydroxylamines	Acetaminophen, ethacrynic acid, bromobenzene
Glycine conjugation	Glycine	Acyl-CoA glycine transferase (mitochondria)	Acyl-CoA derivatives of carboxylic acids	Salicylic acid, benzoic acid, nicotinic acid, cinnamic acid, cholic acid, deoxycholic acid
Sulfation	Phosphoadenosyl phosphosulfate	Sulfotransferase (cytosol)	Phenols, alcohols, aromatic amines	Estrone, aniline, phenol, 3-hydroxycoumarin, acetaminophen, methyldopa
Methylation	S-Adenosylmethionine	Transmethylases (cytosol)	Catecholamines, phenols, amines	Dopamine, epinephrine, pyridine, histamine, thiouracil
Water conjugation	Water	Epoxide hydrolase (microsomes) (cytosol)	Arene oxides, cis-disubstituted and monosubstituted oxiranes Alkene oxides, fatty acid epoxides	Benzopyrene 7,8-epoxide, styrene 1,2-oxide, carbamazepine epoxide Leukotriene A <sub>4</sub>

These rows are not included  
and also last two columns

\* Certain Conjugation leads to formation of Reactive Oxygen species and drug toxicities.

- Example: (1) Acet glucuronide of NSAID (non-steroidal Anti inflammatory drugs)  
(2) O-sulfation of N-hydroxy acetyl amino fluorine  
(3) N-sulfation of isoniazid  
(4) Sulfation of prodrugs as minoxidil.  
(5) Morphine 6-glucuronide is more potent than Morphine.

\* Several drugs may be metabolised transformed to ROS (Reactive Oxygen Spec)

\* Some Toxic rxns may become apparent at high drug dose, especially if alternative detoxification mechanism is overwhelmed or detoxifying co-substrates are depleted



\* an example is acetaminophen

(paracetamol) - induced hepatotoxicity, it is normally undergoes glucuronation and sulfations which make 99% of excreted metabolites. and the alternative p450 dependent pathway counts for 1%

\* as long GSH is available for conjugation → no hepatotoxicity.

\* At high paracetamol dose with absence of GSH the toxic metabolites accumulate and cause hepatotoxicity.


\* Administration of N-acetyl cysteine (Antidote) with 8-16 hours after acetaminophen overdose protect from hepatotoxicity. and no effect of administration of GSH because it can not cross cell membrane.


\* **Enzyme Induction:** it means enhanced rate of enzyme synthesis or reduce rate of degeneration

\* which result in accelerated drug metabolism and usually decrease of pharmacological effect

\* toxicity may increase if the drug is metabolise to active metabolites.

\* induction usually starts at the gene level.





ii) iii)

Done By: Abd Arrahman Dabbas